The issue of compliance for oral agents in BC is not new, and adherence to oral hormonal therapy (HT) in hormone-positive (HR+)/human epidermal growth factor 2 negative (HER2−) BC patients may be lower than expected or perceived by prescribers due to a variety of barriers [5,6,7,8]. Here, ERBB2 is linked to breast cancer.